written on 04.04.2014
Tags:
,

Amgen, GSK part on fast-selling Prolia, mostly

TAGS: ,

GlaxoSmithKline and Amgen are parting ways on Prolia, their comarketed osteoporosis med that's been among the fastest-growing products approved in the last few years. Amgen will take over the task in most areas under their agreement, leaving GSK freer to buckle down on some new launches of its own.

Latest Report